Compare uniQure N.V. Ordinary Shares (QURE) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
uniQure N.V. Ordinary Shares vs TransMedics Group Inc — how do they compare? uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B), while TransMedics Group Inc trades at $75.48 (market cap $2.74B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and uniQure N.V. Ordinary Shares is more actively traded (2,488,780 versus 1,025,926). Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and TransMedics Group Inc for 24 Days on average.
| QURE | TMDX | |
|---|---|---|
Market Cap | $1.48B | $2.74B |
Volume | 2,488,780 | 1,025,926 |
Sector | Health | Health |
52-Week High | $70.59 | $150.42 |
52-Week Low | $9.03 | $61.99 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $728.62M | $3.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TMDX trades at $79.14, up 1.23% on the day, but faces a bearish technical outlook with recent earnings misses in Q1 and Q2 2026. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Recent news highlights insider buying and a new CFO appointment, alongside multiple legal investigations into fiduciary duties.
The stock presents a mixed outlook; analyst consensus is bullish with a $99.63 price target, but near-term risks include earnings volatility, legal scrutiny, and a declining net cash flow trend. Investors should weigh solid fundamentals against execution and sentiment risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
